Status:
COMPLETED
Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Stomach Neoplasm
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
" Hepatic artery variants are occasionally seen, especially 20-30% of aberrant left hepatic artery. In radical gastrectomy, decision for aberrant left hepatic artery(ALHA) ligation should consider the...
Eligibility Criteria
Inclusion
- Patients diagnosed with gastric adenocarcinoma pathologically before surgery
- Patients aged between 20 to 80
- Patients with an ECOG 0 or 1
- Patients who were confirmed the presence of aberrant left hepatic artery before or during surgery
Exclusion
- Patients with abnormal liver function test befor surgery
- Patients who diagnosed liver cirrhosis or infectious liver disease
- Patients who underwent liver resection, or chemotherapy for gastric cancer
- Patients planned for combined liver resection or cholecystectomy during gastrectomy
Key Trial Info
Start Date :
December 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 12 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05971069
Start Date
December 17 2021
End Date
June 12 2023
Last Update
August 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GangnamSeverance Hospital
Seoul, South Korea